Anti-angiogenic activity of inositol hexaphosphate (IP6).

A significant anticancer activity of the naturally occurring carbohydrate inositol hexaphosphate (IP(6)) has been reported against numerous cancer models. Since tumors require angiogenesis for growth and metastasis, we hypothesize that IP(6) reduces tumor growth by inhibiting angiogenesis. Because angiogenesis depends on the interaction between endothelial and tumor cells, we investigated the effect of IP(6) on both. IP(6) inhibited the proliferation and induced the differentiation of endothelial cells in vitro; the growth of bovine aortic endothelial cells (BAECs) evaluated by MTT proliferation assay was inhibited in a dose-dependent manner (IC(50) = 0.74 mM). The combination of IP(6) and vasostatin, a calreticulin fragment with anti-angiogenic activity, was synergistically superior in growth inhibition than either compound. IP(6) inhibited human umbilical vein endothelial cell (HUVEC) tube formation (in vitro capillary differentiation) on a reconstituted extracellular matrix, Matrigel, and disrupted pre-formed tubes. IP(6) significantly reduced basic fibroblast growth factor (bFGF)-induced vessel formation (P < 0.01) in vivo in Matrigel plug assay. Exposure of HepG2, a human hepatoma cell line, to IP(6) for 8 h, resulted in a dose-dependent decrease in the mRNA levels of vascular endothelial growth factor (VEGF), as assessed by RT-PCR. IP(6) treatment of HepG2 cells for 24 h also significantly reduced the VEGF protein levels in conditioned medium, in a concentration-dependent manner (P = 0.012). Thus, IP(6) has an inhibitory effect on induced angiogenesis.

[1]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Agarwal,et al.  Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. , 2000, Biochemical and biophysical research communications.

[3]  A. Parent,et al.  An interaction between inositol hexakisphosphate (IP6) and insulin-like growth factor II receptor binding sites in the rat brain. , 1994, Neuroreport.

[4]  A. Shabsigh,et al.  Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. , 1999, Biology of reproduction.

[5]  S. Hecht,et al.  Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. , 1997, Cancer research.

[6]  A. Shamsuddin,et al.  IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. , 1998, Anticancer research.

[7]  J. York,et al.  A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. , 1999, Science.

[8]  A. Passaniti,et al.  The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth , 1995 .

[9]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[10]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[11]  S. Shears.  Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. , 1996, Sub-cellular biochemistry.

[12]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[13]  Judah Folkman,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994 .

[14]  O. Larsson,et al.  Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate. , 1997, Science.

[15]  R. Agarwal,et al.  Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. , 2000, Carcinogenesis.

[16]  S. De Flora,et al.  ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[18]  K. Tanikawa,et al.  Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. , 1998, Human pathology.

[19]  A. Shamsuddin,et al.  Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. , 1990, Carcinogenesis.

[20]  Jiwei Yang,et al.  Telomerized human microvasculature is functional in vivo , 2001, Nature Biotechnology.

[21]  Sandra Ferry,et al.  Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkappaB-mediated cell survival pathway. , 2002, Carcinogenesis.

[22]  L. Rosen,et al.  Angiogenesis inhibition in solid tumors. , 2001, Cancer journal.

[23]  G. Yang,et al.  Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. , 1995, Carcinogenesis.

[24]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[25]  P. Hawkins,et al.  Characterization of metal ion-induced [3H]inositol hexakisphosphate binding to rat cerebellar membranes. , 1993, The Journal of biological chemistry.

[26]  B. Reddy,et al.  Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea. , 1997, Carcinogenesis.

[27]  G. Yang,et al.  Comparison of pure inositol hexaphosphate and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. , 1997, Nutrition and cancer.

[28]  J. York,et al.  A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. , 2000, Science.

[29]  A. Shamsuddin,et al.  Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. , 1998, Anticancer research.

[30]  A. Shamsuddin,et al.  Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells. , 2003, Anticancer research.

[31]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[32]  R. Agarwal,et al.  Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. , 2003, Carcinogenesis.

[33]  Y. Oshika,et al.  © 1998 Cancer Research Campaign , 2022 .

[34]  A. Shamsuddin,et al.  Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans , 2001, BioFactors.

[35]  K. Sakaguchi,et al.  Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth , 1998, The Journal of experimental medicine.

[36]  A. Shamsuddin,et al.  Mammary tumor inhibition by IP6: a review. , 1999, Anticancer research.

[37]  P. Berggren,et al.  Inositol hexakisphosphate stimulates non-Ca2+-mediated and primes Ca2+-mediated exocytosis of insulin by activation of protein kinase C. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[39]  A. Shamsuddin,et al.  G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). , 2001, Anticancer research.

[40]  J. Folkman,et al.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.

[41]  R. Agarwal,et al.  Impairment of erbB 1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU 145 cells , 2000 .

[42]  A. Shamsuddin,et al.  Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). , 1993, Carcinogenesis.

[43]  M. S. Lee,et al.  Hypoglycemia-induced VEGF expression is mediated by intracellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells. , 2001, International journal of molecular medicine.

[44]  R. Agarwal,et al.  In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate , 2004, Clinical Cancer Research.

[45]  W. Berdel,et al.  Efficacy and safety of thalidomide in patients with acute myeloid leukemia. , 2002, Blood.

[46]  K. W. Kim,et al.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.

[47]  A. Passaniti,et al.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[48]  A. Shamsuddin,et al.  [3H]phytic acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. , 1993, The Journal of nutrition.

[49]  T. P. Pretlow,et al.  Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. , 1992, Carcinogenesis.

[50]  G. Yang,et al.  Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. , 1996, Anticancer research.

[51]  A. Shamsuddin.  Anti-cancer function of phytic acid , 2002 .

[52]  K. Zaner,et al.  Release of calreticulin from neutrophils may alter C1q-mediated immune functions. , 1997, The Biochemical journal.

[53]  J. Eaton,et al.  Antioxidant functions of phytic acid. , 1990, Free radical biology & medicine.

[54]  A. Shamsuddin,et al.  Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. , 1989, Carcinogenesis.

[55]  R. Motzer,et al.  Phase II trial of thalidomide for patients with advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  L. Ellis,et al.  EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells , 2001, British Journal of Cancer.

[57]  A. Shamsuddin,et al.  Inhibition of rat mammary carcinogenesis by inositol hexaphosphate (phytic acid). A pilot study. , 1993, Cancer letters.

[58]  Y. M. Lee,et al.  Anti‐angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica , 2000, International journal of cancer.

[59]  J. Pouysségur,et al.  p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts* , 1998, The Journal of Biological Chemistry.

[60]  L. Ellis,et al.  Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. , 1999, Cancer research.

[61]  L. Claesson‐Welsh,et al.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.

[62]  A. Shamsuddin,et al.  IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. , 1998, Anticancer research.

[63]  A. Shamsuddin,et al.  Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. , 1989, Carcinogenesis.

[64]  Ivana Vucenik,et al.  Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. , 2003, The Journal of nutrition.

[65]  D. Fabian,et al.  Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. , 1992, Cancer letters.

[66]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[67]  J. Folkman,et al.  Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.

[68]  E. Acosta,et al.  Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma , 2000, Cancer Chemotherapy and Pharmacology.

[69]  E. Jaffe,et al.  Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. , 2000, Blood.

[70]  K. Sakaguchi,et al.  Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. , 1999, Blood.

[71]  A. Shamsuddin.  Metabolism and cellular functions of IP6: a review. , 1999, Anticancer research.

[72]  M. Hanley,et al.  Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. , 1995, Biochemical pharmacology.